Dianthus Therapeutics, Inc. (DNTH)

In the past six months, Dianthus Therapeutics' stock has been impacted by earnings reports, clinical trial milestones, public offerings, analyst coverage and ratings, insider activity, and stock price performance. The company reported earnings on March 9, 2026, with shares gaining +21.5%. Dianthus announced an early "GO" decision for its Phase 3 CAPTIVATE CIDP trial on March 9, 2026, and top-line results for the Phase 2 MoMeNtum trial in MMN are anticipated in the second half of 2026. In March 2026, Dianthus announced and closed an upsized $719 million underwritten public offering. Wolfe Research initiated coverage with an Outperform recommendation and later upgraded it to a Strong Buy rating, and Wells Fargo also initiated coverage with an Overweight recommendation. Insiders have sold more stock than they have bought in the past three months, with sales totaling $26,564,008.00. The share price as of April 2, 2026, was $86.00, representing a significant increase of 433.50% over the previous year.

Information regarding demand seasonality for Dianthus Therapeutics, Inc.'s products and services is not explicitly available. As a clinical-stage biotechnology company, its primary activities revolve around drug development and clinical trials rather than commercial product sales, which typically exhibit demand seasonality.

Dianthus Therapeutics, Inc. (DNTH) is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, operating within the Biotechnology & Medical Research sector. The company aims to design and deliver monoclonal antibodies with improved selectivity and potency. Its lead product candidate, DNTH103 (claseprubart), is in mid- to late-stage clinical trials for generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The company also has DNTH212 in its pipeline, with Phase 1 healthy volunteer data anticipated in the second half of 2026.

Dianthus Therapeutics, Inc. is headquartered in New York, New York, and Waltham, Massachusetts. The company's shareholder base is primarily from the United States, accounting for 86.7% of its shareholders.

Dianthus Therapeutics' reputation in the past year appears to be largely positive, driven by progress in its clinical pipeline and favorable analyst sentiment. The company has received "Buy" and "Strong Buy" ratings from multiple research firms, indicating market optimism. Positive clinical trial results have contributed to a strong perception of the company's ability to advance its drug candidates. The company's stock performance also reflects positive investor confidence.

Dianthus Therapeutics, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 71.60% to 81.56% of the company's stock is owned by institutional investors, insiders hold about 0.15% to 8.15% of the stock, while public companies and individual investors own approximately 9.96% to 18.29%. Major institutional owners and shareholders include Fmr Llc, Wellington Management Group Llp, and Vanguard Group Inc, among others. Peter Harwin is noted as owning the most shares among individual investors.